Recent Updates
Recently added Catalysts

bion

Phase 3

Overactive Bladder | Unknown | Nephrology |Boston Scientific Corporation|Last Updated: Nov 19, 2013

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedSHAM_CONTROLLED
Total Trials1
Total Enrollment118

FDA Designations

No designations recorded

Clinical trial landscape

bion · 2 trials · 2 indications

Phase 3 2
NCT00131573An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency SyndromeOveractive Bladder
COMPLETED118 Analytics
NCT00080470An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge IncontinenceUrinary Incontinence
COMPLETED148 Analytics
PHASE3COMPLETED
An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome
Overactive BladderUnlock trial analytics
PHASE3COMPLETED
An Implantable Microstimulator for the Chronic Treatment of Refractory Urinary Urge Incontinence
Urinary IncontinenceUnlock trial analytics

Study Endpoints

Primary Endpoints

Average Number of Voids Per Day
12 months
Freedom From Major Complications
5 years
Number of Leaks Per Day
12 months
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
1EXPERIMENTALStimulation On from Initial Activation up to the 12 month post-activation. Stimulation Off from 12 months post-activation until 45 days after the 12 month visit. Stimulation On from 45 days post 12 month visit and on.
2SHAM_COMPARATORNo stimulation until 45 days post-implant. Stimulation On from 45 days post-implant and on.

Interventions

NameTypeDescription
bionDEVICEbattery powered bion microstimulator
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites11

Key Inclusion criteria: * Age 18 years and above. * Diagnosed with urinary urgency-frequency syndrome. * Have no reported history of urethral obstruction/stricture, bladder calculi or bladder tumor. * Have normal upper urinary tract function. * Be capable of giving informed consent. * Be capable an...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about bion

What is Bion used for?

Bion is an implantable microstimulator being developed for the treatment of overactive bladder and urinary incontinence. It is intended for patients with refractory urinary urge incontinence and urinary urgency-frequency syndrome. The device is currently in Phase 3 clinical development and is not yet approved by the FDA.

Who makes Bion?

Bion is being developed by Boston Scientific Corporation, a medical device company traded on the New York Stock Exchange under the ticker symbol BSX. The company is conducting clinical trials to evaluate the safety and effectiveness of the implantable microstimulator for urinary conditions.

What phase is Bion in?

Bion is in Phase 3 clinical development. Two Phase 3 trials have been completed, one for urinary incontinence and one for overactive bladder. The device remains investigational and has not received FDA approval. Boston Scientific is the sponsor of these trials.

What clinical trials is Bion in?

Bion has been studied in two completed Phase 3 trials. NCT00080470 evaluated the implantable microstimulator for refractory urinary urge incontinence with 148 participants, and NCT00131573 assessed it for urinary urgency-frequency syndrome with 118 participants. Both trials were conducted in the United States.

How does Bion work?

Bion is an implantable microstimulator designed to deliver electrical stimulation to treat overactive bladder and urinary incontinence. The device is implanted to provide chronic stimulation, aiming to modulate nerve activity related to bladder function. It is being studied as a treatment for patients with refractory symptoms.